Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,403 across all filing types
Latest filing 2022-09-23 Earnings Release
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Earnings Release Classification · 1% confidence The document is a press release dated September 23, 2022, announcing clinical data for the drug lacutamab from the Phase 2 TELLOMAK trial, presented at an EORTC CLTG congress. It contains key financial/clinical highlights, management quotes, and tables summarizing preliminary results. This format—an initial announcement of key results for a specific period or event (a clinical trial update)—is characteristic of an Earnings Release (ER) or a general announcement. Since it is not a full annual report (10-K), a comprehensive interim report (IR), or a transcript (CT), and it focuses on presenting new data highlights rather than just announcing the publication of a report (RPA), the most fitting category is Earnings Release (ER), as clinical data releases often serve the same function as financial earnings releases for biotech/pharma companies—announcing period performance/updates to the market. It is a formal announcement of results, not a regulatory filing like a 10-K or a general RNS. FY 2022
2022-09-23 French
Inside Information / Other news releases
Earnings Release Classification · 1% confidence The document is a press release dated September 23, 2022, announcing clinical data presentation from the ongoing Phase 2 TELLOMAK trial for the drug lacutamab. It details preliminary results (ORR, safety profile) presented at a scientific meeting (EORTC CLTG Annual Meeting). This type of announcement, focusing on clinical trial results and scientific updates, is characteristic of an Earnings Release (ER) or a general Investor Presentation (IP) if it were a slide deck. Since it is a formal press release summarizing key data points and future plans, it aligns best with an Earnings Release (ER), which typically covers recent operational/clinical highlights, or potentially an Investor Presentation (IP) if the content were structured as a presentation summary. Given the structure—headline announcement of data, quotes from CMO/Investigator, summary tables of results, and forward-looking statements—it functions as a primary communication of recent performance/progress, fitting the 'ER' definition (Initial announcement of quarterly/periodical financial results [or key operational/clinical results]). It is not a full financial report (10-K or IR), nor is it a transcript (CT) or a formal regulatory filing announcement (RPA/RNS) about a report release. ER is the most appropriate fit for a clinical data announcement press release. FY 2022
2022-09-23 English
6-K
Foreign Filer Report
2022-09-15 English
Half yearly financial reports and audit reports/limited reviews / Half yearly financial report
Interim / Quarterly Report Classification · 1% confidence The document is titled 'INNATE PHARMA SA HALF-YEAR FINANCIAL REPORT JUNE 30, 2022'. It contains comprehensive interim condensed consolidated financial statements, management review, balance sheets, income statements, and notes to the financial statements for the six-month period ending June 30, 2022. It is a substantive financial report rather than an announcement or a summary, fitting the definition of an Interim/Quarterly Report. H2 2022
2022-09-15 English
Rapports financiers et d'audit semestriels/examens réduits / Modalités de mise à disposition du rapport financier semestriel
Earnings Release Classification · 1% confidence The document is a press release from Innate Pharma detailing their financial results for the first half of 2022. It includes a summary of financial performance, cash position, and updates on their drug development pipeline. While it contains financial data, it is structured as an earnings release announcement (highlighting key results and upcoming conference calls) rather than a full interim financial report. According to the 'Menu vs Meal' rule, this is the announcement of the results, not the full report itself. Therefore, it is classified as an Earnings Release. H1 2022
2022-09-15 French
INNATE PHARMA S.A. 6-K
Foreign Filer Report
2022-09-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.